Thank you, Tiffany and thank you all for joining us today. We are excited to share the ongoing progress of our novel modifier gene therapy platform across all three clinical programs, as well as recent announcement regarding our OCU200 biologic candidate, which I will highlight later in the p...
11/19/2024 07:02 AM ESTGlobeNewswireOcugen Announces Compelling Preliminary Data for OCU410-a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration 11/08/2024 06:45 AM ESTGlobeNewswireOcugen Provides Business Update with Third Quarter ...
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cel...
Ocugen, Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing gene and cell therapies, biologics, and vaccines that improve health for patients across the globe. Its technology pipeline includes modifier gene therapy platform, regenerative medicine cel...
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative...
allergy and infectious diseases for early clinical studies for the ocu500 program; and a strategic partnership with cansino biologics inc. for manufacturing its modifier gene therapy pipeline product candidates. the company was founded in 2013 and is headquartered in malvern, pennsylvania. hide sector...
OCGN earnings call for the period ending September 30, 2024. Motley Fool Transcribing | Nov 8, 2024 Ocugen (OCGN) Q2 2024 Earnings Call Transcript OCGN earnings call for the period ending June 30, 2024. Motley Fool Transcribing | Aug 8, 2024 ...
Ocugen identifies itself as a biopharmaceutical company focused on developing gene therapies to cure blindness and developing a vaccine to save lives from COVID-19. The Company's main developments are a modifier gene therapy platform based on nuclear hormone receptors to generate therapies for patient...
and benefit profile of OCU400 for any mutations relative to any risk of treatment. The approval of an Expanded Access Program for OCU400 further supports the gene agnostic mechanism of action for this novel modifier gene therapy. We look forward to working with clinicians, patients and the RP ...